Information Provided By:
Fly News Breaks for March 8, 2018
Mar 8, 2018 | 12:44 EDT
BTIG analyst Dane Leone raised his price target for Bluebird Bio to $250 to reflect recent acquisitions of peer companies, meetings with the management team, and conversations at the American Society for Blood and Marrow Transplantation conference. Following the acquisition of Juno, Bluebird stands as the leading independent company with integrated genetic and cell therapy capabilities, Leone tells investors in a research note. He believes, however, that Bluebird management has no interest in selling the company within the near term. The analyst says his new price target reflects the company's long-term value proposition. Leone keeps a Buy rating on Bluebird Bio.
News For BLUE;JUNO From the Last 2 Days
There are no results for your query BLUE;JUNO